Headache in a time of Covid-19

Headache as a feature of Covid-19 Headache is common in patients with Covid-19. In the first review of the neurological aspects of Covid-19, a study of 214 patients in Wuhan with confirmed SARS-Cov-2 infection, Mao et al noted headache in 28 (13.1%) patients.(1) This figure has subsequently been replicated in a metanalysis of over 3000 … Read more

Covid-19 neurology update: 20th April 2020

Information continues to accrue on the potential neurological effects of infection with SARS-Cov-2, the virus that causes Covid-19. In the last few days, three papers have appeared detailing cases of acute inflammatory neuropathies associated with Covid-19. A paper in the New England Journal of Medicine presents five Italian patients with Guillain-Barré syndrome (GBS),(1) a condition … Read more

The indirect neurological consequences of Covid-19

In a blog published yesterday, I summarised the current medical and scientific literature on the known or suspected direct neurological effects of SARS-Cov-2. It’s a fast-moving situation: in the last 24 hours the New England Journal of Medicine, perhaps the most prestigious general medical journal there is, has published a letter from a team of … Read more

Neurological consequences of Covid-19

There is as yet very little in the published literature on the neurological consequences of Covid-19 (the disease caused by infection with SARS-Cov-2). The first extensive report – a retrospective consecutive case series of 214 patients from Wuhan, China, with either moderate or severe COVID-19, was published in JAMA Neurology in early April 2020.(1) Of … Read more

LHC – Covid-19 update

Following the Government’s advice today to avoid all “non-essential” travel, I have made the decision to conduct all London Headache Centre consultations remotely until further notice. I will be very happy to review new and old patients via telephone, Skype, or other video conferencing methods. Consultation slots will continue to be available by contacting The … Read more

CGRP and migraine 3: mAbs 2019

In the last blog, I told the story of the development of monoclonal antibodies (mAbs) against CGRP, from their first appearance in the literature in 2007 to their licensing in the USA and Europe in 2018-19. In the third blog in this sequence I will go into a little more detail on the evidence for … Read more

CGRP and migraine 2: rise of the mAbs

In the last blog, I took the CGRP story from the 1980s to the 2000s, from the fortuitous discovery of triptans to advent of monoclonal antibody technology, and the first inklings that it could be applied to the treatment of migraine. Useful drugs do not always start out as such. One transformation, seen time and … Read more

My disclosures 2019

I am employed by Buckinghamshire Healthcare NHS Trust for 10.5 PA (42 hours) per week. In addition to that I am engaged in private practice at BMI The Chiltern Hospital and The Medical Chambers Kensington. I have received honoraria in the last 10 years for advisory boards and lecturing from Novartis, TEVA Pharmaceuticals, Lilly, and … Read more